{"id":2391,"date":"2019-10-05T22:59:25","date_gmt":"2019-10-05T20:59:25","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=2391"},"modified":"2024-06-19T14:44:25","modified_gmt":"2024-06-19T12:44:25","slug":"cancer-immunotherapy","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/cancer-area\/molecular-mechanisms-and-experimental-therapy-in-oncology-program-oncobell\/cancer-immunotherapy\/","title":{"rendered":"Cancer Immunotherapy"},"content":{"rendered":"\n
The Cancer Virotherapy and Immunotherapy Group explores new anticancer treatments based on oncolytic adenoviruses and other immunotherapies. The group aims to design and evaluate oncolytic adenoviruses as antitumour agents for various solid tumours. The main lines of research are tumour targets, intratumoural diffusion through stromal barriers and oncolytic immunotherapy. The group also participates in other immunotherapy projects based on mutanome-derived cancer neoepitopes and cellular immunotherapy with modified NK cells.\u00a0\u00a0<\/p>\n
Research for oncolytic adenovirus tumour targets (Ramon Alemany)<\/p>\n
Intratumoural diffusion of oncolytic adenoviruses through stromal barriers (Ramon Alemany)<\/p>\n
Oncolytic immunotherapy (Ramon Alemany \/ Rafa Moreno)<\/p>\n
Immunotherapy based on cancer neoepitopes (Ramon Alemany \/ Rafa Moreno \/ Josep Maria Piulats \/ V\u00edctor Moreno)<\/p>\n
Mesenchymal stem cells as carriers of oncolytic adenoviruses (Rafa Moreno)<\/p>\n
Laboratory analysis associated with clinical trials with oncolytic adenoviruses (Rafa Moreno and Marcel Costa)<\/p>\n\t\t\t\t\tSelected Publications<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t 20FIS039. Phase II stUdy of ALoCelyvir in patientS with mEtastatic Uveal Melanoma (PULSE-UM)<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 694.346,29\u20ac. 2020-2025. PI: Piulats Rodr\u00edguez, Josep Mar\u00eda.<\/p>\n 21FIS038. Venciendo la resistencia a la inmunoterapia en tumores no antig\u00e9ncios ni inmunog\u00e9nicos usando el c\u00e1ncer de pr\u00f3stata como modelo. El estudio HEAT-CRPC<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 133.100\u20ac. 2021-2025. PI: Piulats Rodr\u00edguez, Josep Mar\u00eda.<\/p>\n FIS21131. RICORS TERAV<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 169.412,1\u20ac. 2022-2024. PI: Alemany Bonastre, Ram\u00f3n.<\/p>\n FIS23018. C\u00e9lulas troncales mesenquimales como veh\u00edculo celular de un adenovirus oncolitico codificante de un activador biespecifico de c\u00e9lula T (BiTE) frente a EGFR para el tratamiento del glioblastoma<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 95.625\u20ac. 2024-2026. PI: Moreno Oli\u00e9, Rafael.<\/p>\n MCI21009. Inducci\u00f3n de muerte celular inmunog\u00e9nica en tumores mediante el uso de adenovirus oncol\u00edticos armados<\/strong>. Ministerio de Ciencia e Innovaci\u00f3n. Budget: 266.200\u20ac. 2021-2024. PI: Alemany Bonastre, Ram\u00f3n.<\/p>\n 2022-160-1. ESTUDIO FASE II, ABIERTO DE LA EFICACIA PRELIMINAR DE SITRAVATINIB EN COMBINACI\u00d3N CON TISLELIZUMAB EN PACIENTES CON MELANOMA METAST\u00c1SICO UVEAL CON HEP\u00c1TICAS MET\u00c1STASIS<\/strong>. Grupo Espa\u00f1ol Multidisciplinar de Melanoma (GEM). Budget: 5.000\u20ac. 2022- . PI: Piulats Rodr\u00edguez, Josep Mar\u00eda.<\/p>\n 18ACL149. A PHASE I\/II, OPEN-LABEL, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF IMCGP100 USING THE INTRA-PATIENT ESCALATION DOSING REGIMEN IN PATIENTS WITH ADVANCED UVEALMELANOMA<\/strong>. Immunocore Ireland Limited. Budget: 154.384\u20ac. 2018- . PI: Piulats Rodr\u00edguez, Josep Mar\u00eda.<\/p>\n 17ACL119. TRITON 3: UN ESTUDIO MULTIC\u00c9NTRICO, ALEATORIZADO, ABIERTO DE FASE 3 DE RUCAPARIB VERSUS ELECCI\u00d3N DEL M\u00c9DICO PARA PACIENTES CON C\u00c1NCER DE PR\u00d3STATA METAST\u00c1SICO RESISTENTE A LA CASTRACI\u00d3N ASOCIADO CON DEFICIENCIA DE RECOMBINACI\u00d3N HOM\u00d3LOGA<\/strong>. CLOVIS ONCOLOGY, INC. . Budget: 77.183,86\u20ac. 2017-2026. PI: Piulats Rodr\u00edguez, Josep Mar\u00eda.<\/p>\n PNJ22025. Servei d’Estudis de Pot\u00e8ncia in vitro e in vivo per a c\u00e8l\u00b7lules NK derivades d’iPSC en el marc d’un projecte de recerca pel Banc de Sang i Teixits. Banc de Sang i Teixits<\/strong>. Budget: 68.600\u20ac. 2022- . PI: Moreno Oli\u00e9, Rafael.<\/p>\n 19PNJ011. ESTUDIO DE FASE I PARA EVALUAR LA SEGURIDAD, LA TOLERABILIDAD Y LA EFICACIA DE VCN-01 EN COMBINACI\u00d3N CON DURVALUMAB (MEDI4736) EN PACIENTES CON CARCINOMA DE C\u00c9LULAS ESCAMOSAS DE CABEZA Y CUELLO RECURRENTE \/ METAST\u00c1SICO<\/strong> . VCN BIOSCIENCES SL. 2019-2023. PI: Alemany Bonastre, Ram\u00f3n.<\/p>\n\t\t\t\t\tTechnology transfer<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tPAT005-ADENOVIRUS ONCOL\u00cdTICOS PARA EL TRATAMIENTO DEL C\u00c1NCER The viruses developed by the group are currently being tested in clinical trials conducted by biotechnology companies. These include VCN Biosciences, which is a spin-off of the group. The group also analyses viral and immunological parameters in patient samples.<\/p>\n\t\t\t\t Cancer immunotherapy Summary The Cancer Virotherapy and Immunotherapy Group explores new anticancer treatments based on oncolytic adenoviruses and other immunotherapies. The group aims to design and evaluate oncolytic adenoviruses as antitumour agents for various solid tumours. The main lines of research are tumour targets, intratumoural diffusion through stromal barriers and oncolytic immunotherapy. The group also […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":448,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-2391","page","type-page","status-publish","hentry"],"publishpress_future_action":{"enabled":false,"date":"2024-09-14 17:47:43","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"_links":{"self":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/2391"}],"collection":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/comments?post=2391"}],"version-history":[{"count":10,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/2391\/revisions"}],"predecessor-version":[{"id":24325,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/2391\/revisions\/24325"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/448"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/media?parent=2391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\nIP: Ramon Alemany
\nES200901201\nPAT040-ADENOVIRUS COMPRISING AN ALBUMIN-BINDING MOIETY
\nIP: Ramon Alemany
\nEP14382162\nLicense: Adenovirus comprising an albumin-binding molety
\nPI: Dr. Ramon Alemany
\nLicense: Adenovirus onol\u00edticos para el tratamiento del c\u00e1ncer
\nPI: Dr. Manel Cascall\u00f3\n\t\t\t\t\tMore Information<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t\n
\n\t\tAlemany Bonastre, Ramon\n\t<\/h4>\n
\n\t\t\n\t\tralemany@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t
\n
\n\t\tPiulats, Rodriguez, Josep Maria\n\t<\/h4>\n
\n\t\t\n\t\tjpiulats@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tPrincipal investigators\n\t<\/h2>\n\t\t\t\t
\n
\n\t\tAlemany Bonastre, Ramon\n\t<\/h4>\n
\n\t\t\n\t\tralemany@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t
\n
\n\t\tPiulats, Rodriguez, Josep Maria\n\t<\/h4>\n
\n\t\t\n\t\tjpiulats@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t
\n
\n\t\tMoreno Oli\u00e9, Rafael\n\t<\/h4>\n
\n\t\t\n\t\trmoreno@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tRELATED LINKS\n\t<\/h4>\n
\n\t\t\n\t\tProCURE\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\tSpanish Adenovirus Network\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tTeam\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tGroup leaders\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPrincipal investigators\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tClinical researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPostdoctoral researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPredoctoral researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tScientific support\t\t\t\t<\/a>\n\t\t\t\t\t\tGroup leaders\n\t\t\t\t\t\t\t\t\t\t\t
\n
\n
\n
\n
\n
\n
\n\t\tRelated news\n\t<\/h2>\n\t\t\n\t\t\t\t<\/a>\n\t\t\tScientists present an oncolytic virus targeting NK cells with great antitumor potential<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t12\/01\/2024\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tA drug that prevents DNA reparation could improve the survival of patients with one of the most aggressive prostate cancers<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t23\/02\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tWe close a 2021 full of science!<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t30\/12\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL receives more than one and a half million euros from AECC to fund cancer research projects<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t17\/11\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tA new drug increases the life expectancy of patients with very aggressive intraocular cancer<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t27\/09\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tMolecular analysis could improve the early detection and prevention of endometrial cancer<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t17\/06\/2019\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tEl Grupo CataLands Solidaris da 10.000 euros al Programa ProCURE<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t31\/07\/2017\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL joins the ADVANCECAT project to promote advanced therapies in Catalonia<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t11\/11\/2016\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tAECC grants two IDIBELL research projects<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t30\/01\/2013\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tManuel Ramirez: ”Once we have made the step from the laboratory to the patient, we must return to the laboratory for further progress”<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t14\/06\/2011\t\t\t\t\t\t\t\n\t\t\n\n","protected":false},"excerpt":{"rendered":"